Bedaquiline plus delamanid for XDR tuberculosis

Lancet Infect Dis. 2016 Mar;16(3):294. doi: 10.1016/S1473-3099(16)00047-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Diarylquinolines / therapeutic use*
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Extensively Drug-Resistant Tuberculosis / surgery*
  • Health Services Accessibility*
  • Humans
  • Male
  • Nitroimidazoles / therapeutic use*
  • Oxazoles / therapeutic use*

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Nitroimidazoles
  • Oxazoles